<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03392376</url>
  </required_header>
  <id_info>
    <org_study_id>REG-169-2017</org_study_id>
    <nct_id>NCT03392376</nct_id>
  </id_info>
  <brief_title>Agents Intervening Against Delirium in Intensive Care Unit</brief_title>
  <acronym>AID-ICU</acronym>
  <official_title>Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Research in Intensive Care (CRIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scandinavian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Centre of Applied Social Science (VIVE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delirium is a frequent condition in the Intensive Care Unit (ICU) with no existing
      evidence-based treatment. The aim of the AID-ICU study is to assess the benefits and harms of
      haloperidol treatment for the management of ICU acquired delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delirium among critically ill patients in the intensive care unit (ICU) is a common condition
      associated with increased morbidity and mortality. No evidence-based treatment exist of this
      condition. Haloperidol is the most frequently used agent to treat ICU-related delirium, but
      according to the available literature there is no firm evidence of efficacy and safety of
      this intervention. AID-ICU aims to assess the benefits and harms of haloperidol in adult,
      critically ill patients with delirium in the ICU.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive out of the hospital within 90 days post-randomization</measure>
    <time_frame>90 days</time_frame>
    <description>Number of days alive and out of hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days alive without delirium or coma in the ICU</measure>
    <time_frame>Until ICU discharge, maximum 90 days</time_frame>
    <description>Number of days where patients are both alive and free of delirium and coma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with one or more serious adverse reactions and/or the total number of serious adverse reactions to haloperidol compared with placebo</measure>
    <time_frame>Measured every day from inclusion until ICU discharge, maximum 90 days</time_frame>
    <description>Serious adverse reactions are: Anaphylactic reactions, Agranulocytosis, Pancytopenia, Ventricular arrhythmia, Extrapyramidal symptoms, Tardive dyskinesia, Malignant Neuroleptic Syndrome, Acute hepatic failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of escape medicine and dosage of escape medicine per patient</measure>
    <time_frame>Measured every day from inclusion until ICU discharge, maximum 90 days</time_frame>
    <description>Proportion of patients receiving escape medicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive without mechanical ventilation within 90 days postrandomisation</measure>
    <time_frame>Measured every day from inclusion until ICU discharge, maximum 90 days</time_frame>
    <description>Number of days where patients are both alive and free of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Landmark mortality 1 year post-randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (five level)</measure>
    <time_frame>1 year</time_frame>
    <description>EQ-5D-5L total score 1 year post-randomisation (1-5 of each of the five domains)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (overall self assessment)</measure>
    <time_frame>1 year</time_frame>
    <description>EQ-Visual Analogue Scale 1 year post-randomisation (0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function 1 year after randomisation at selected sites</measure>
    <time_frame>1 year</time_frame>
    <description>Repeated Battery for the Assesment of Neuropsychological Status score 1 year post-randomisation at selected sites (40-150)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive function 1 year after randomisation at selected sites</measure>
    <time_frame>1 year</time_frame>
    <description>Trail Making Test 1 year post-randomisation at selected sites (40-150)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A health economic analysis</measure>
    <time_frame>90 days</time_frame>
    <description>The analytic details will be based on the primary results of the trial (cost-benefit or cost-minimisation analyses)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Haloperidol injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.
Other name: Serenase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0,9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol Injection</intervention_name>
    <description>ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.</description>
    <arm_group_label>Haloperidol injection</arm_group_label>
    <other_name>Serenase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline (0,9%)</intervention_name>
    <description>ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute admission to the ICU AND

          -  Age â‰¥ 18 years AND

          -  Diagnosed delirium with validated screening Tool as either CAM-ICU or ICDSC

        Exclusion Criteria:

          -  Contraindications to haloperidol

          -  Habitual treatment with any antipsychotic medication or treatment with antipsychotics
             in the ICU prior to inclusion

          -  Permanently incompetent (e.g. dementia, mental retardation)

          -  Delirium assessment non-applicable (coma or language barriers)

          -  Withdrawal from active therapy

          -  Fertile women (women &lt; 50) with positive urine human chorionic gonadotropin (hCG) or
             plasma hCG.

          -  Consent according to national regulations not obtainable

          -  Patients under coercive measures by regulatory authorities

          -  Patients with alcohol-induced delirium (Delirium Tremens)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OIe Mathiesen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Perner, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JÃ¸rn Wetterslev, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Copenhagen Trial Unit, Center for Clinical Intervention Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lone Musaeus Poulsen, MD</last_name>
    <phone>+4547326451</phone>
    <email>lmp@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Christine Andersen-Ranberg, MD</last_name>
    <phone>+4547326493</phone>
    <email>ncan@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. Intensive Care, Aabenraa Hospital</name>
      <address>
        <city>Aabenraa</city>
        <zip>6200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Thee, MD</last_name>
      <email>carsten.thee@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven-Olaf Weber, MD</last_name>
      <email>s.weber@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Bodil Steen Rasmussen, MD, PhD</last_name>
      <email>bodil.steen.rasmussen@rn.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Perner, MD, PhD</last_name>
      <email>anders.perner@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Lindhart, MD</last_name>
      <email>anne.lindhart.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Mohr, MD</last_name>
      <email>thomas.mohr@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sofie Andreasen, MD</last_name>
      <email>anne.sofie.andreasen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Herning Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Troels Bek Jensen, MD</last_name>
      <email>trojense@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Robert Winding, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Nordsjaelland Hospital</name>
      <address>
        <city>HillerÃ¸d</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Bestle, MD, PhD</last_name>
      <email>morten.bestle@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, HolbÃ¦k Hospital</name>
      <address>
        <city>HolbÃ¦k</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Henrik BÃ¼low, MD</last_name>
      <email>hhbu@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nilanjan Dey, MD</last_name>
      <email>nilanjan.dey@vest.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Borup, MD</last_name>
      <email>morten.borup@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Zealand University Hospital, KÃ¸ge</name>
      <address>
        <city>KÃ¸ge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Christine Andersen-Ranberg, MD</last_name>
      <email>ncan@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Hans Christian Boesen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stine Estrup, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, NykÃ¸bing Falster Hospital</name>
      <address>
        <city>NykÃ¸bing Falster</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helle Scharling Pedersen, MD</last_name>
      <email>hbpn@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of intensive care, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Gramstrup Nielsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Zealand University Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Plank Pedersen, MD,</last_name>
      <email>hppd@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Andi Iversen, MD</last_name>
      <email>saiv@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, SÃ¸nderborg Hospital</name>
      <address>
        <city>SÃ¸nderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siv Leivdal, MD</last_name>
      <email>siv.leivdal@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00120</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna HÃ¤stbacka, MD, PhD</last_name>
      <email>johanna.hastbacka@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of intensive care, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Outi Inkinen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of intensive care, UniversitÃ¤tsklinikum Schleswig-Hostein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Kott, MD, DMSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurosurgical Intensive Care, San Gerardo Hospital, Monza.</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Citerio, MD, PhD</last_name>
      <email>giuseppeciterio@unimib.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis George Romundstad, MD, PhD</last_name>
      <email>luisro@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Intensive Care, Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus Caballero, MD</last_name>
      <email>jecablo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cric.nu/aid-icu/</url>
    <description>LINK to the AID-ICU webpage</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU Delirium</keyword>
  <keyword>Haloperidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

